Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy
Kendrick Yim(Brigham and Women's Hospital), Mark A. Preston(Brigham and Women's Hospital), Matthew Mossanen(Massachusetts General Hospital), Keyan Salari(Broad Institute), Timothy N. Clinton, Filipe L.F. Carvalho(Brigham and Women's Hospital), Michelle S. Hirsch(Perinatal Institute), Adam S. Feldman(Massachusetts General Hospital), Matthew Wszolek(Brigham and Women's Hospital), Sarah L. Mott(University of Iowa), Chin‐Lee Wu(Massachusetts General Hospital), Adam S. Kibel(Brigham and Women's Hospital), Kent W. Mouw(Massachusetts General Hospital), Kevin Melnick(Brigham and Women's Hospital), Affan Zafar(Brigham and Women's Hospital), Graeme S. Steele(Brigham and Women's Hospital), Natalie M. Rizzo(Brigham and Women's Hospital), Michael A. O’Donnell(University of Iowa Health Care)
Urologic Oncology Seminars and Original Investigations
September 9, 2023
Cited by 31
Related Papers
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance
|Science|2015|718
DNA Damage and Repair Biomarkers of Immunotherapy Response
|Cancer Discovery|2017|673
Isolation and Characterization of Circulating Tumor Cells from Patients with Localized and Metastatic Prostate Cancer
|Science Translational Medicine|2010|537